Clinical characteristics of the study population
| Parameters | All n=65 | Survivors n=49 | Non-survivors n=16 | P values |
| Age, years | 63.5±14.8 | 63.2±15.3 | 64.4±13.3 | 0.601 |
| Male, n (%) | 22 (34) | 12 (24) | 9 (56) | 0.030 |
| Height, cm | 168±9 | 167±8 | 170±11 | 0.367 |
| Weight, kg | 73.0 (63.5; 88.0) | 70 (63.5; 87.5) | 81.5 (61.8; 88.8) | 0.508 |
| BMI, kg/m² | 26.0 (22.9; 29.5) | 26.0 (22.9; 29.5) | 26.4 (22.3; 30.7) | 0.897 |
| BSA, m² | 1.82 (1.67; 1.99) | 1.80 (1.66; 1.98) | 1.93 (1.67; 2.00) | 0.337 |
| Heart rate, 1/min | 72 (65; 84) | 71 (65; 84) | 82 (74; 88) | 0.017 |
| Serological measurements | ||||
| Haemoglobin, g/dL | 13.7 (11.7; 15.2) | 13.0 (11.7; 15.0) | 14.4 (11.5; 15.6) | 0.442 |
| NTproBNP, pg/mL | 668 (182; 3500) | 457 (150; 1572) | 4755 (520; 7541) | 0.004 |
| cTnT, ng/L | 12 (5; 27) | 10 (5; 23) | 26 (9; 63) | 0.031 |
| Clinical classification, n (%) | ||||
| WHO FC I | 3 (5) | 33 (6) | 0 (0) | – |
| WHO FC II | 21 (32) | 18 (37) | 3 (19) | – |
| WHO FC III | 32 (49) | 21 (43) | 11 (69) | – |
| WHO FC IV | 9 (14) | 7 (14) | 2 (12) | – |
| WHO FC>II | 41 (63) | 28 (57) | 13 (81) | 0.085 |
| 6MWT, m | 348 (264; 490) | 379 (278; 527) | 304 (209; 444) | 0.102 |
| PH group | ||||
| 1—PAH | 31 (48) | 24 (49) | 7 (44) | – |
| 3—ILD, EAA, COPD | 14 (22) | 9 (18) | 5 (31) | – |
| 4—CTEPH | 19 (29) | 15 (31) | 4 (25) | – |
| 5—multifactorial aetiology | 1 (1) | 1 (2) | 0 (0) | – |
Total number of patients of a category is complemented by the percentage of the according group, n (%). Variability of values is given as mean with (±SD) for parameters with normal distribution, or otherwise as median with percentiles (25%; 75%).
6MWT, 6 min walk test; BMI, body mass index; BSA body surface area; COPD, chronic obstructive pulmonary disease; CTEPH, chronic thromboembolic pulmonary hypertension; cTnT, cardiac troponin T; EAA, exogenous allergic alveolitis; FC, functional class; ILD, idiopathic lung disease; NTproBNP, N-terminal pro-brain natriuretic peptide; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension.